Feeds:
Posts
Comments

Posts Tagged ‘Chemotherapy’

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: In trying to better predict a patient’s response to chemotherapy, a team of investigators at the State University of New Jersey has identified a way to better manipulate a gene product to cause cancer cells to die. READ MORE>

Read Full Post »

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>

Read Full Post »

URO TODAY: Scientists in Texas have been analysing data on the considerable number of castration-refractory prostate cancer patients who experience an initial PSA surge/flare-up while having chemotherapy. READ MORE>

Read Full Post »

ONCOLOGY STAT: Researchers have identified four clinical risk factors that reduce the likelihood of achieving a 30%-or-greater decline in serum PSA during the three months after the start of chemotherapy. READ MORE>

Read Full Post »

URO TODAY: Docetaxel plus estramustine chemotherapy represents an active and well-tolerated treatment for Japanese hormone-refractory prostate cancer patients. READ MORE>

Read Full Post »

PROSTABLOG NZ: John has now moved to the stage of needing chemotherapy for his advanced prostate cancer, but the government-subsidised version in NZ has been surpassed by a more effective drug – at $5000 a dose. That’s way beyond Mary’s bank balance. READ MORE>

Read Full Post »

ONCOLOGY STAT: Researchers have identified four clinical risk factors that reduce the likelihood of achieving a 30%-or-greater decline in serum prostate-specific antigen during the 3 months after the start of chemotherapy. READ MORE>

Read Full Post »

ADVANCED PROSTATE CANCER: A new drug has shown promise in prolonging life and reducing pain for men with advanced prostate cancer and for whom chemotherapy in not working.  READ MORE>

Once we have failed docetaxel therapy (chemo therapy) we have very few options available to control advanced prostate cancer.

There is a recent report about a clinical trial using a new potential drug, Patupilone.

Patupilone has shown some evidence that it exhibits a limited positive effect in the pre-clinical setting in taxane resistant models of prostate cancer, meaning prostate cancer that does not respond or no longer responds to taxotere therapy.

Read Full Post »

Older Posts »